Perspectivas Médicas sobre Carcinomatose Peritoneal: Avanços Terapêuticos e Prognóstico

Mândala Borges  Dias; Jordanna  Porto Inácio; Guilherme Cristovam Pina; Natália  Quinan Bittar Nunes; Luciano Souza Longhi; Lucas De Souza Wascheck; Analou Messias Castro; Nilson Afonso Da Silva Júnior; Larissa Martins Flores; Mônica Maciel Guimarães; Patrik  Michel Dos Anjos Silva; Raquel  Pereira Da Silva; Matheus Mendes Maranhão; Vitor Linhares Ribeiro; Letícia Gonçalves Da Costa; Leonardo Ferreira De  Oliveira; Camila Freitas Barbosa; Thais De Andrade Paula; Marcela Marques Abbes

doi:10.36557/2674-8169.2024v6n8p4299-4308

Authors

Mândala Borges Dias Médica pela Universidade Evangélica de Goiás – UniEvangélica
Jordanna Porto Inácio Graduanda em Medicina pela UniATENAS – Campus Sete Lagoas https://orcid.org/0009-0002-2409-8180
Guilherme Cristovam Pina Médico pela Universidade Evangélica de Goiás – UniEvangélica https://orcid.org/0000-0003-0299-7679
Natália Quinan Bittar Nunes Médica com Residência na área de Clínica médica pelo Hospital Estadual de Urgências Governador Otávio Lage de Siqueira HUGOL Goiânia - Goiás https://orcid.org/0009-0006-0391-0415
Luciano Souza Longhi Médico pela Universidade Federal de Goiás https://orcid.org/0009-0001-6894-2286
Lucas De Souza Wascheck Médico pela Universidade Federal de Goiás
Analou Messias Castro Médica pela Universidade Federal do Pará (UFPA) https://orcid.org/0009-0000-7102-3443
Nilson Afonso Da Silva Júnior Médico pela Universidade de Gurupi https://orcid.org/0009-0008-8408-9183
Larissa Martins Flores Médica Residente em Clínica médica pelo Instituto Ortopédico de Goiânia https://orcid.org/0000-0002-6336-9142
Mônica Maciel Guimarães Médica residente em Oncologia Clínica pelo Hospital de Base do Distrito Federal
Patrik Michel Dos Anjos Silva Médico Residente em Cirurgia Geral pela Universidade Evangélica de Goiás – UniEvangélica Anápolis – Goiás https://orcid.org/0009-0009-3870-8614
Raquel Pereira Da Silva Médica Residente em Clínica Médica pelo Hospital Estadual de Urgências Governador Otávio Lage de Siqueira Goiânia – Goiás HUGOL https://orcid.org/0009-0007-3763-0224
Matheus Mendes Maranhão Médico pela Universidade Evangélica de Goiás - UniEvangélica
Vitor Linhares Ribeiro Médico Residente em Clínica Médica pelo Hospital de Urgências Governador Otávio Lage - HUGOL https://orcid.org/0000-0003-1157-6008
Letícia Gonçalves Da Costa Médica Residente Médica em Radiologia pela UEPA- Universidade Estadual do Pará
Leonardo Ferreira De Oliveira Médico pela Faculdade CERES - FACERES https://orcid.org/0009-0003-2528-3158
Camila Freitas Barbosa Médica pelo Centro Universitário UniFG https://orcid.org/0009-0009-7835-8516
Thais De Andrade Paula Médica com Residência em Clínica Médica pela Universidade Federal de Goiás https://orcid.org/0000-0003-4023-6918
Marcela Marques Abbes Médica Residente em Clínica Médica pela Santa Casa de Misericórdia de Goiânia

DOI:

https://doi.org/10.36557/2674-8169.2024v6n8p4299-4308

Keywords:

Peritoneal Carcinomatosis, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, ; Immunotherapy, Targeted Therapies

Abstract

Peritoneal carcinomatosis (PC) is an oncological condition characterized by the dissemination of malignant tumor cells within the peritoneal cavity, frequently associated with gastrointestinal neoplasms such as colorectal, gastric, and ovarian cancers. Historically, PC carried an extremely poor prognosis, traditionally treated with palliative systemic chemotherapy, whose effectiveness was limited by the peritoneal barrier, which hinders the penetration of chemotherapeutic agents. The objective of this study was to critically analyze the practices and advancements in the treatment of peritoneal carcinomatosis, focusing on combined interventions of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), as well as evaluating the emerging role of immunotherapy and targeted therapies in improving patient survival and quality of life. This study utilized a narrative literature review, analyzing scientific articles published between 2000 and 2024 from PubMed, Scopus, and ScienceDirect databases. The results indicate that the combination of CRS and HIPEC has become the gold standard in treating PC, especially in cases of gastrointestinal and gynecological tumors. Studies have shown that this approach can significantly prolong patient survival. The addition of immunotherapy and targeted therapies, which offer a more personalized approach, has shown promise in enhancing treatment efficacy and reducing resistance. However, challenges such as treatment resistance and toxicity remain, highlighting the ongoing need for research and the development of new therapeutic strategies. The treatment of PC has significantly evolved with the introduction of CRS and HIPEC, which have improved survival rates in selected cases. The future management of PC will depend on the continuous development of new therapies and the ability to tailor these approaches to the specific needs of each patient, aiming to maximize clinical benefits and improve quality of life.

Downloads

Download data is not yet available.

References

BEAL, E. W. et al. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. American Journal of Surgery, v. 219, n. 3, p. 478-483, 2020.

CEELEN, W.; DEMUYTERE, J.; DE HINGH, I. Hyperthermic Intraperitoneal Chemotherapy: A Critical Review. Cancers (Basel), v. 13, n. 13, p. 3114, 2021. Disponível em: https://doi.org/10.3390/cancers13133114. Acesso em: 9 ago. 2024.

JÄGER, M. et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Research, v. 72, n. 24, p. 24-32, 2012.

KANG, D.; KIM, I. H. Molecular mechanisms and potential rationale of immunotherapy in peritoneal metastasis of advanced gastric cancer. Biomedicines, v. 10, n. 6, p. 1376, 2022. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35729580/. Acesso em: 9 ago. 2024.

KLEBER, J.; ZHOU, J. Y.; WEBER, F.; BITTERER, F.; HAUER, P.; KUPKE, P.; KRONENBERG, K.; GEISSLER, E. K.; SCHLITT, H. J.; HORNUNG, M.; HUTCHINSON, J. A.; WERNER, J. M. Immune profile of patients with peritoneal carcinomatosis selected for CRS-HIPEC therapy. Cancer Immunology, Immunotherapy, v. 72, n. 11, p. 3867-3873, 2023. Disponível em: https://doi.org/10.1007/s00262-023-03515-2. Acesso em: 9 ago. 2024.

QUÉNET, F. et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, v. 22, n. 2, p. 256-266, 2021.

SUGARBAKER, P. H. Management of peritoneal-surface malignancy: The surgeon's perspective. Journal of Clinical Oncology, v. 14, n. 3, p. 564-574, 1996.

YAN, G.; ZHANG, K.; YAN, L.; ZHANG, Y. Long-term survival outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of hepatocellular carcinoma patients. World Journal of Surgical Oncology, v. 22, n. 1, p. 144, 2024. Disponível em: https://doi.org/10.1186/s12957-024-03426-1. Acesso em: 9 ago. 2024.

Medical Perspectives on Peritoneal Carcinomatosis: Therapeutic Advances and Prognosis

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

How to Cite

Issue

Section

License

Make a Submission

Indexadores

Brazilian Journal of Implantology and Health Sciences (ISSN 2674-8169)